The peptide drug market in my country has further expanded, and these companies are worth recommending

Polypeptide drugs are mainly used for the treatment of chronic diseases.
At present, the international peptide drugs are mainly distributed in the treatment of 7 major diseases, including rare diseases, tumors, diabetes, gastrointestinal tract, orthopedics, immunity, cardiovascular diseases, etc.
, among which rare diseases, Tumor and diabetes are the "troika" driving the peptide drug market, and the other four fields also have heavy varieties on the market.
Representative varieties include liraglutide, dulaglutide, somaglutide, leuprolide, teriparatide, octreotide, exenatide and so on
.
Data shows that from 2016 to 2020, China's peptide drug sales have risen from 24.
19 billion yuan to 29.
56 billion yuan, a growth rate of over 15%.
It is estimated that China's peptide drug sales will reach 38.
71 billion yuan in 2021
.
According to the industry, with the introduction of policies to encourage the research and development of innovative drugs and promote the consistency evaluation of generic drugs, it is expected that more innovative peptide drugs and peptide generic drugs with significant clinical effects will be approved for marketing in the future, which will further promote the peptide drug market in China.
Expansion
.
It is understood that there are nearly a hundred local peptide companies in China, and the author will take you to take a look at three relatively large-scale peptide drug companies
.
Hanyu Pharmaceuticals Hanyu Pharmaceuticals has been focusing on the research and development, production and sales of peptide drugs since its launch.
Its main products include three series of peptide drug preparations, peptide drug bulk drugs and customized peptides
.
The company is an important API supplier in the field of peptides, with a variety of specialty API products such as liraglutide, glatiramer, atosiban, terlipressin, desmopressin, and ganirelix
.
Hanyu Pharmaceutical has been engaged in the production of peptide APIs for many years, and has built core barriers in terms of technology, customers, and production capacity
.
It is understood that the Wuhan production base under its subsidiary covers a total area of ​​360 acres, the overall planned construction area is 270,000 square meters, and the investment is about 900 million yuan.
The main product is peptide APIs.
It is an important API production base of the company and can be effective.
Ensure the self-supply of APIs for the internal preparation business, and also have sufficient production capacity to produce APIs for overseas
.
Shuangcheng Pharmaceutical Shuangcheng Pharmaceutical's peptide drugs mainly include Thymus for Injection ("Jitai"), which is an immune-enhancing drug, and is mainly used for the treatment and treatment of various types of liver diseases, tumors, geriatrics and infectious diseases.
The body’s immunity is improved.
The product has passed the national drug supervision and management injection generic drug quality and efficacy consistency evaluation and obtained the marketing license issued by the Italian Medicines Agency; injection somatostatin is used for severe acute esophageal varices bleeding, severe the treatment of acute bleeding gastric or duodenal ulcers, such as diabetic ketoacidosis
.
At present, Shuangcheng Pharmaceutical has passed the GMP inspections of the US FDA and the EU EMA.
The inspections include peptide APIs and sterile injections
.
In terms of raw materials, the company’s Thymus Method has passed the technical review of the Italian Food and Drug Administration (AIFA); the two DMFs submitted to the US FDA have successfully passed the review
.
In terms of preparations, Shuangcheng Pharmaceuticals has successfully obtained the new ANDA approval for thymus for injection approved by the Italian Food and Drug Administration (AIFA), and bivalrudine for injection has passed the US FDA marketing permit and has been exported to the United States; paclitaxel for injection (Albumin-binding type) US IND was approved, solid preparation, US ANDA (Memantine Hydrochloride Tablets) was approved; Thymosin for injection and Bivacrudine for injection were approved for consistency evaluation
.
As a domestic peptide drug company, Sino Bio has always established its brand with innovative peptide drug pharmaceutical research services and peptide product customized production services, based on the large-scale production and sales of raw materials
.
At the same time enter the preparation market, form the main business of peptide innovative drug pharmaceutical research services and peptide product customized production services parallel to the production and sales of peptide APIs and preparations, and strengthen the company's competitive advantage in the peptide field through coordinated development between businesses , The formation of performance growth points
.
After years of accumulation of experience in the research and development and production of peptide drugs and industrial development, Senno Bio has become one of the few domestic peptide drugs in the field of peptide drugs that has the entire industrial chain of peptide drug development, production and sales.
It is a powerful peptide drug in China.
One of the synthesis and production technology platforms, and also one of the market competitors in the global regulated market peptide generic drug industry chain
.
At present, the company's main product lines cover multiple therapeutic areas such as digestive system, immune system diseases, anti-tumor, chronic hepatitis B, diabetes, and obstetrics.
It is one of the domestic peptide drug manufacturers with relatively complete product lines
.
According to data, as of the end of June 2021, the company has bivalrudine, eptifibatide, icatibant, liraglutide, octreotide acetate, ziconotide, teriparatide, 8 Ganirec products have been registered and activated by the US DMF
.